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SREBP-2Akt is an essential protein kinase for cell growth, proliferation, and survival. Perturbed Akt regulation is asso-
ciated with a number of human diseases, such as cancer and diabetes. Recently, evidence has emerged that
Akt is involved in the regulation of the sterol-regulatory element binding proteins, which are master tran-
scriptional regulators of lipid metabolism. This offers a means by which synthesis of new membrane can
be coordinated with cell growth and proliferation. However, the link between Akt and sterol-regulatory ele-
ment binding protein-2, the major isoform participating in cholesterol regulation, is relatively unexplored. In
the present study, we employed insulin-like growth factor-1 as an inducer of Akt signalling, and showed that
it increased sterol-regulatory element binding protein-2 activation acutely (within 1 h). This insulin-like
growth factor-1-induced sterol-regulatory element binding protein-2 activation was blunted when Akt was
inhibited pharmacologically or molecularly with small interfering RNA. Furthermore, we employed a
rapalog heterodimerisation system to speciﬁcally and rapidly activate Akt, and found that sterol-regulatory
element binding protein-2 activation was increased in response to Akt activation. Together, this study
provides compelling evidence that Akt contributes to the acute regulation of cholesterol metabolism
through activating sterol-regulatory element binding protein-2.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Akt (also known as protein kinase B) is a serine/threonine protein
kinase downstream of phosphatidylinositol 3-kinase (PI3K). It is essen-
tial for regulating cell growth, proliferation, survival, and the interaction
with environmental stimuli [1]. The PI3K/Akt pathway is initiated by
ligands, such as insulin-like growth factor-1 (IGF-1), binding to and
activating receptor tyrosine kinases (reviewed in [2]). These receptors
are autophosphorylated, and this recruits PI3K to the membrane. PI3K
is activated and generates phosphatidylinositol-3,4,5-trisphosphate
from phosphatidylinositol-4,5-bisphosphate by phosphorylation. This
in turn recruits inactive Akt via its Pleckstrin Homology domain, as
well as two activating kinases, phosphoinositide-dependent kinase 1
(PDK1) [3] and mammalian Target of Rapamycin (mTOR) Complex 2Chinese hamster ovary-7; DN-
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l rights reserved.[4]. Once activated, Akt phosphorylates a large number of substrates,
leading to their activation or inhibition.
Akt is implicated in many diseases, most notably in cancer and
diabetes, due to aberrant Akt activity (for reviews, see [5,6]). More-
over, Akt has recently been implicated in a novel form of regulation,
lipid metabolism, through the sterol-regulatory element binding pro-
teins (SREBPs) [7].
SREBPs are master transcriptional regulators of lipid metabolism.
There are three mammalian isoforms of the SREBPs; SREBP-1a, -1c,
and -2 [8]. SREBP-1c regulates genes involved in fatty acid metabo-
lism, and SREBP-2 regulates genes involved in cholesterol metabolism,
while SREBP-1a targets both sets of genes. SREBPs are produced as a
precursor bound to the endoplasmic reticulum (ER) membrane, com-
plexed with SREBP cleavage-activating protein (Scap). Scap acts as an
escort protein and senses sterol levels for end-product feedback regu-
lation [9]. When sterol levels are sufﬁcient, Scap adopts a conforma-
tion [10] which is held back by a retention protein called insulin-
induced gene [11], preventing the activation of SREBP. When sterol
levels are low, Scap escorts the SREBP precursor from the ER to the
Golgi in coatomer protein II vesicles [12]. At the Golgi, SREBP is se-
quentially cleaved by two proteases, site-1 protease and site-2 prote-
ase to become activated. Themature SREBP fragment is transported to
the nucleus to transcriptionally upregulate lipogenic target gene ex-
pression, which restores sterol homeostasis via lipid synthesis and up-
take. Thismature active form of SREBP-2 is thus the focus of this study.
There is emerging evidence implicating PI3K/Akt in the regulation
of lipid metabolism through the SREBPs [7]. Coordination between
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duce the lipids for new membrane synthesis, which in turn is re-
quired for growing and proliferating cells [13]. Most work thus far
has focussed on the SREBP-1c isoform, and these ﬁndings are mostly
consistent [7]. The link between Akt and the SREBP-2 isoform, how-
ever, is relatively unexplored and is contentious. Our laboratory iden-
tiﬁed a novel input into SREBP-2 activation through the involvement
of the PI3K/Akt pathway [14]. The ER-to-Golgi transport of Scap/
SREBP-2 was inhibited by a potent inhibitor of PI3K, LY294002, and
a dominant-negative form of Akt (DN-Akt). DN-Akt inhibits endoge-
nous Akt activity by competing for upstream kinases that activate
Akt [15], and this can prevent the activation of endogenous kinases
other than Akt [15]. As LY294002 is an inhibitor of PI3K, an early com-
ponent in the pathway, it can also inhibit downstream kinases other
than Akt. Moreover, as with many pharmacological inhibitors, it is
also reported to inhibit other targets, such as mTOR and casein
kinase-2, with a similar potency as required for PI3K [16]. Thus,
these approaches are susceptible to non-speciﬁc effects [7].
In the present study, we set out to investigate the link between
Akt and SREBP-2 activation, using more selective tools than were
available at the time of our previous study [14]. These include more
direct approaches to reduce Akt activation than PI3K inhibitors, and
more acute time-points to minimise indirect effects. In our previous
work [14], statins were used to stimulate SREBP-2 activation, which
is more related to cholesterol homeostasis than cell growth or prolif-
eration. Here, we employed IGF-1, known to signal cell growth and
proliferation via the Akt pathway [17], and a rapalog heterodimerisa-
tion system for a more speciﬁc and rapid induction of Akt activation,
and thus explore the interaction between Akt signalling and SREBP-2
regulation.
2. Materials and methods
2.1. Materials
Chinese hamster ovary-7 (CHO-7) and CHO cells stably expressing
green ﬂuorescent protein fused to Scap (CHO/pGFP-Scap cells) [18]
were generous gifts of Drs. Michael S. Brown and Joseph L. Goldstein
(UT Southwestern Medical Center, Dallas, TX). Akt (pan) antibody
and phosphorylated Akt (pAkt; S473) antibody were from Cell Signal-
ing Technology (Beverly, MA). Dulbecco's Modiﬁed Eagle's Medium/
Ham's Nutrient Mixture F-12 (DMEM/F12), newborn calf serum,
Lipofectamine 2000, Lipofectamine LTX, Opti-MEM I reduced serum
medium, ProLong Gold Antifade Reagent with DAPI, and Superscript
III Reverse Transcriptase were from Invitrogen (Carlsbad, CA). Akt in-
hibitor IV, Akt inhibitor V (Triciribine), Akt inhibitor VIII (Akti-1/2),
and PhosphoSafe Extraction Reagent were from Merck (Darmstadt,
Germany). IGF-1 was from R&D Systems (Minneapolis, MN). α-tubulin
antibody, bovine serum albumin (BSA), BSA (essentially fatty acid
free), LY294002, LY303511, MG132, Protease Inhibitor Cocktail
(contains AEBSF, Aprotinin, Leupeptin, Bestatin, Pepstatin A and E-64),
TRI reagent, and Wortmannin were from Sigma-Aldrich (St. Louis,
MO). 25-hydroxycholesterol (25HC) was from Steraloids (Newport,
RI). Lipoprotein-deﬁcient serum (LPDS) was prepared from newborn
calf serum as previously described [19]. The Golgi marker plasmid,
dsRed-Monomer-Golgi, encoding the N-terminal portion of human
beta 1,4-galactosyltransferase which is targeted to the trans-medial re-
gion of the Golgi, was from Clontech (Mountain View, CA).
2.2. Methods
2.2.1. Cell culture, pretreatments, and treatments
CHO-7 and CHO/pGFP-Scap cells were maintained in 5% (v/v)
LPDS/DMEM/F12 and were serum-starved overnight in 0.1% (w/v)
BSA (essentially fatty acid free) in DMEM/F12. HepG2 cells were
maintained in 10% FCS/DMEM (low glucose), and serum-starvedovernight in 0.1% BSA (essentially fatty acid free) in DMEM (low
glucose). Where there were pretreatments, the cells were pretreated
in fresh starvationmedia, and then treatments were added to the pre-
treatment media for the indicated length of time. Where there was no
pretreatment, the cells were treated in fresh starvation media. The
cells were pretreated and/or treated with various test agents [added
in dimethylsulfoxide, ethanol, water, or 0.1% (w/v) BSA/phosphate-
buffered saline (PBS)], as indicated in the ﬁgure legends. Within an
experiment, the ﬁnal concentrations of solvent were kept constant
between conditions and did not exceed 0.3% (v/v).
2.2.2. Harvesting protein for Western blot analysis
After treatment, cells were lysed in PhosphoSafe Extraction Re-
agent supplemented with 2% (w/v) SDS, protease inhibitor cocktail,
and phosphatase inhibitor cocktail (50 mM sodium ﬂuoride, 1 mM
sodium orthovanadate, 10 mM sodium pyrophosphate and 10 mM
β-glycerophosphate). For experiments where CHO-7 cells were trans-
fected with siRNA or when the stable Flp-In cell-lines were tested, the
cells were harvested in SDS lysis buffer (10 mM Tris–HCl (pH 7.6),
100 mM sodium chloride, 2% (w/v) SDS) with protease inhibitor
cocktail and phosphatase inhibitor cocktail. Protein concentrations
of the cell lysates were determined using the bicinchoninic acid
assay kit (Thermo Fisher Scientiﬁc, Waltham, MA) according to the
manufacturer's instructions. Equal amounts of protein were mixed
with loading buffer (ﬁnal conc.: 50 mM Tris–HCl (pH 6.8), 2% (w/v)
SDS, 5% (v/v) glycerol, 0.04% (w/v) bromophenol blue, and 1% (v/v)
β-mercaptoethanol), boiled for 5 min, and subjected to SDS-PAGE.
After electrophoresis, the proteins were transferred to a nitrocellulose
membrane for analysis by Western blotting.
2.2.3. Western blotting
Membranes were blocked with 5% (w/v) BSA/PBST [0.1% (v/v)
Tween20 in PBS] ([or 5% (w/v) skimmilk/PBST for 1D2]), and then incu-
bated with primary antibody diluted in 5% (w/v) BSA/PBST. The follow-
ing antibodies were used: Akt (pan), pAkt (S473), IgG-7D4 [a mouse
mAb against the N-terminus of hamster SREBP-2 (amino acids
32–250) [20]; prepared in-house [21]], IgG-1D2 [a mouse mAb
against the N-terminus of human SREBP-2 (amino acids 48–403) [22]
(a generous gift from Dr Bao-Liang Song)], and α-tubulin. The
membrane was then washed in PBST, incubated with secondary
antibody in 5% (w/v) BSA/PBST ([or 1% (w/v) skim milk/PBST for
1D2]), and washed in PBST. The antibodies were visualised by the
enhanced chemiluminescent detection system, and membranes were
exposed to Hyperﬁlm. Proteins were identiﬁed by their predicted
sizes (pAkt/Akt, 56 kDa; α-tubulin, 50 kDa; precursor SREBP-2,
124 kDa; mature SREBP-2, 52 kDa; FRB-Akt, ~75 kDa). Before reprob-
ing, antibodies were removed with stripping buffer (25 mM glycine,
1.5% (w/v) SDS, pH 2).
2.2.4. Densitometry
Protein band intensities from Western blots were quantiﬁed by
densitometry using ImageJ (Version 1.42q) [23]. The bands corre-
sponding to mature SREBP-2 were quantiﬁed to yield relative intensi-
ties (M), with the 1 h +IGF-1 or +rapalog condition set to 1 in each
experiment.
2.2.5. Fluorescence microscopy
CHO/pGFP-Scap cells were seeded on coverslips in duplicate
wells per condition, transfected with dsRed-Monomer-Golgi using
Lipofectamine LTX according to the manufacturer's instructions, and
serum-starved overnight. The cells were refed with starvation
media before they were pretreated with or without Akt inhibitor
VIII for 1 h, and treated in the same media with IGF-1 for a further
4 h. Cells were ﬁxed with 3% (v/v) formaldehyde/PBS and mounted on
glass slides with ProLong Gold Antifade Reagent with DAPI. Images
were obtained using anOlympus FV 1000Confocal InvertedMicroscope
Fig. 1. IGF-1 stimulated SREBP-2 activation, which was reduced by a PI3K inhibitor.
CHO-7 cells were seeded and serum-starved overnight. (A) The cells were then treated
with or without IGF-1 (20 nM) for 0–4 h. (B) The cells were pretreated with or without
LY294002 (20 μM) for 1 h, and then treated with IGF-1 (20 nM) for a further 0–4 h.
25HC (2.5 μM) served as a positive control. Whole cell lysates from (A) and (B) were
subjected to SDS-PAGE and then transferred to nitrocellulose membranes. Membranes
were probed for SREBP-2, pAkt, Akt, and α-tubulin. P and M denote the precursor and
mature forms of SREBP-2, respectively. Western blots are representative of three sepa-
rate experiments, and the relative intensity (M) value represents the densitometric
quantiﬁcation of the mature form of SREBP-2, where the 1 h +IGF-1 condition has
been set to 1.
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557 nm for dsRed, and 405 nm for DAPI.
2.2.6. Quantitative RT-PCR
CHO-7 or HepG2 cells were seeded in triplicate wells per condition
and serum-starved overnight. Cells were refed starvation media con-
taining pretreatments for 1 h, and then treated in the same media
with IGF-1 for 2 h. Cells were harvested for total RNA using TRI re-
agent, essentially according to the manufacturer's instructions. Total
RNA (1 μg) was reverse transcribed to cDNA with Superscript III Re-
verse Transcriptase.
Quantitative real-time PCR (qRT-PCR) was performed using a
Corbett Rotorgene 3000 and analysed using Rotor-Gene Version 6.0
(Build 27) (Corbett Research, Mortlake, NSW). Primers were used to
amplify the cDNA of hamster [14] or human [24,25] low density lipo-
protein receptor (LDLR), 3-hydroxy-3-methylglutaryl-coenzyme A re-
ductase (HMGCR), and the housekeeping control porphobilinogen
deaminase (PBGD). Changes in gene expression levels of LDLR and
HMGCR were normalised to PBGD for each sample.
2.2.7. siRNA transfection
CHO-7 cells were transfected with 200 μM small interfering RNA
(siRNA) [either SignalSilence® Akt siRNA I (#6211) or SignalSilence®
Control siRNA Unconjugated (#6568) (Cell Signaling Technology,
Beverly, MA)] using Lipofectamine 2000 transfection reagent accord-
ing to the manufacturer's instructions, with slight modiﬁcations. With
the modiﬁed protocol, the cells were transfected in half the media
volume, and refed culture medium every 24 h for 48 h without re-
moving the siRNA complexes. The cells were then serum-starved
overnight, and treated with IGF-1 in fresh starvation media for 1 h.
2.2.8. Cloning the pBI-CMV-FRB-Akt-Myc-Myr-2xFKBP-HA-FRT vector,
and creating a stable Flp-In cell-line
A plasmid containing a FRT recombination site and encoding
myristoylated (Myr)-2xFK506-binding protein (FKBP)-HA and
FKBP-rapamycin binding (FRB)-Akt-Myc driven by a bi-directional
CMV promoter was created using polymerase incomplete primer
extension [26]. Firstly, the bi-directional CMV promoter/enhancer
was inserted into pcDNA5/FRT/TO to create pBI-CMV-FRT. Bovine
Akt1 with a C-terminal Myc tag was ampliﬁed from pCMV-WT-Akt-
Myc plasmid [27] and subcloned into the pC4-RHE plasmid encoding
the FRB domain (ARIAD Pharmaceuticals, Cambridge, MA). The FRB-
Akt-Myc was inserted into the destination plasmid, pBI-CMV-FRT.
Myr-2xFKBP-HA from pC4M-F2E (ARIAD Pharmaceuticals, Cambridge,
MA) was similarly introduced into pBI-CMV-FRT in a second cloning
step, yielding the complete expression vector. The resulting pBI-CMV-
FRB-Akt-Myc-Myr-2xFKBP-HA-FRT construct was veriﬁed by sequenc-
ing and used to prepare CHO-7 stable cells generated in-house with
the Flp-In system (Invitrogen, Carlsbad, CA), selecting for single colo-
nies with 200 μg/mL hygromycin B. Empty vector stable cells were pre-
pared using a pcDNA5/FRT/TO empty expression plasmid.
3. Results
3.1. IGF-1 acutely increases SREBP-2 activation
We determined if Akt activation induced by IGF-1 affects SREBP-2
activation within a 4 h time-course in Chinese hamster ovary (CHO)-7
cells, a cell-line commonly employed in cholesterol homeostasis
studies [e.g. 28,29]. IGF-1 increased phosphorylated Akt (pAkt, the
active form) levels within 30 min, and this was sustained for at least
4 h (Fig. 1A).
SREBP-2 activation results from ER-to-Golgi transport and prote-
olysis of precursor SREBP-2 to increase the mature (active) form of
SREBP-2 [9]. This was monitored directly by Western blotting with
an antibody that binds to the N-terminus of SREBP-2, and thereforedetects both precursor and mature forms. With IGF-1 treatment, ma-
ture SREBP-2 was increased, indicating an increase in SREBP-2 activa-
tion (Fig. 1A). The earliest time IGF-1 stimulated a discernable effect
on SREBP-2 activation was at 1 h.
3.2. PI3K inhibition blunts IGF-1-induced SREBP-2 activation
To determine if IGF-1 stimulates SREBP-2 via PI3K within this
time-frame, cells were pretreated with a pharmacological inhibitor
of PI3K, LY294002 [30], for 1 h to repress basal PI3K activity before
treating with IGF-1 for a further 0–4 h (Fig. 1B). An oxygenated sterol,
25HC, was included as a positive control as it is known to potently in-
hibit SREBP-2 activation [31]. LY294002 suppressed the IGF-1 stimu-
lation of pAkt and SREBP-2 activation, while the inactive analogue,
LY303511 [32], had no effect (Supplementary Fig. 1A). Another selec-
tive PI3K inhibitor, wortmannin, also effectively reduced both Akt and
SREBP-2 activation (Supplementary Fig. 1B). These results demon-
strate that IGF-1 increases SREBP-2 activation acutely via PI3K, poten-
tially via Akt.
3.3. A speciﬁc Akt inhibitor reduces SREBP-2 levels
Although the major downstream effector of PI3K is Akt, LY294002
can also affect other targets downstream of PI3K [16]. To investigate
the role of Akt in IGF-1-mediated SREBP-2 activation, a speciﬁc phar-
macological inhibitor of Akt was utilised — Akt inhibitor VIII,
isozyme-selective, also called Akti-1/2 [33]. This compound binds to
the Pleckstrin Homology domain of Akt to prevent its activation,
and has become one of the Akt inhibitors of choice [34]. Akt inhibitor
VIII demonstrated a complete inhibition of Akt activation, and also
decreased SREBP-2. Both the mature transcription factor as well as
Fig. 2. A speciﬁc Akt inhibitor decreased SREBP-2, and ER-to-Golgi trafﬁcking of Scap.
(A) and (B) CHO-7 cells were seeded and serum-starved overnight. (A) The cells
were then pretreated with or without Akt inhibitor VIII (AktiVIII; 5 μM) for 1 h, and
then treated with or without IGF-1 (20 nM) for a further 0–4 h. 25HC (2.5 μM) served
as a positive control. (B) Cells were pretreated with or without AktiVIII (5 μM) and/or
MG132 (10 μM) for 1 h, and then treated with or without IGF-1 (20 nM) for a further
1 h. Whole cell lysates from (A) and (B) were subjected to SDS-PAGE and then trans-
ferred to nitrocellulose membranes. Membranes were probed for SREBP-2, pAkt, Akt,
and α-tubulin. P and M denote the precursor and mature forms of SREBP-2, respective-
ly. Western blots are representative of three separate experiments, and the relative in-
tensity (M) value represents the densitometric quantiﬁcation of the mature form of
SREBP-2, where the +IGF-1 condition has been set to 1. (C) CHO/pGFP-Scap cells
were seeded and serum-starved overnight. Cells were then pretreated with or without
AktiVIII (5 μM) for 1 h, followed by IGF-1 treatment (20 nM) for 4 h. Cells were ﬁxed
andmounted on slides with mounting buffer. Fluorescence microscopy was performed.
Representative of at least three ﬁelds of view per condition.
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unaffected by Akt inhibitor VIII treatment in this time frame (data
not shown).
To determine if Akt inhibitor VIII increased SREBP-2 turnover, we
inhibited proteasomal degradation with MG132. This did not rescue
the precursor, but partially rescued mature SREBP-2, consistent with
accelerated proteasomal degradation of the active form of SREBP-2
when Akt is inhibited (Fig. 2B).
As a complementary measurement of SREBP-2 transport from the
ER to the Golgi, CHO cells stably expressing the SREBP escort protein,
Scap, fused to GFP [18] were employed. These cells exhibit normal
cholesterol homeostasis, and allow for convenient visualisation of
the localisation of SREBP-2, which colocalises with Scap. When pre-
treated with Akt inhibitor VIII, cells tended to exhibit a diffuse, retic-
ular pattern that is typical of ER localisation similar to the non-treated
condition (Fig. 2C). This pattern is distinct from the characteristic
Golgi juxtanuclear ﬂuorescence of the IGF-1 alone treatment. This re-
sult is consistent with the inhibition of Akt disrupting ER-to-Golgi
transport of SREBP-2 as seen in Fig. 2B, where there was a decrease
in mature SREBP-2.
3.4. Additional Akt inhibitors also reduce SREBP-2 activation
It is recommended that the cellular effects of kinase inhibition
should be observed with two structurally-unrelated kinase inhibitors
[35]. Therefore, two additional Akt inhibitors were used to determine
the correlation between acutely inhibiting Akt activity and SREBP-2
activity (1 h). Akt inhibitor IV and V were selected, as they do not af-
fect PI3K, unlike other commercially available inhibitors such as Akt
inhibitor I, II and III, which are analogues of phosphatidylinositol [36].
When used at previously published concentrations [37], Akt inhib-
itor IV, V, and VIII all decreased pAkt and mature SREBP-2 (Fig. 3A).
Mature SREBP-2 protein levels mirrored SREBP-2 transcriptional
activity, with Akt inhibitors IV and V also downregulating two
SREBP-2 target genes, LDLR and HMGCR (Fig. 3B). Akt inhibitor VIII
had a marginal effect, which approached statistical signiﬁcance
(p=0.077 for HMGCR, student's paired t-test). Importantly, we con-
ﬁrmed these results in a human liver cell-line, HepG2, using the in-
hibitor with the greatest effect on Akt and SREBP-2 activation, Akt
inhibitor IV (Supplementary Fig. 2).
Overall, pharmacological inhibitors indicated that inhibiting Akt
resulted in a concomitant reduction in mature SREBP-2 levels and
downstream transcriptional activity.
3.5. Silencing Akt using siRNA decreases IGF-1-induced SREBP-2 activity
To complement our pharmacological inhibitors, we utilised a more
speciﬁc molecular approach; gene silencing to knock down endoge-
nous Akt expression. IGF-1-stimulated SREBP-2 activation was
blunted when Akt was knocked down (Fig. 4A). Once again, this
strengthens the link between Akt and SREBP-2 activation.
3.6. Rapid activation of Akt increases SREBP-2 activation
Our results thus far have focused on Akt inhibition approaches,
and have relied on activating Akt with a growth factor, IGF-1, through
a signalling pathway. Therefore, we employed a more speciﬁc and
rapid system for activating Akt, similar to approaches used in previ-
ous studies [38,39]. Brieﬂy, we cloned a bi-directional CMV-driven
vector encoding FRB-Akt-Myc and myristoylated (Myr)-2xFKBP-HA
(Supplementary Fig. 3A). This uses rapalog (a non-immunosuppressive
derivative of rapamycin) to induce the heterodimerisation of the
FRB and FKBP fragments. We stably expressed the construct in a
CHO-7 Flp-In cell-line. Under basal conditions, FKBP is anchored to
the plasma membrane by the Myr signal while FRB-Akt-Myc is cyto-
plasmic (Supplementary Fig. 3B). When rapalog is added, it binds to
AB
Fig. 3. Inhibitors of Akt decrease SREBP-2 activation and target gene expression. CHO-7
cells were seeded, serum-starved overnight, and then pretreated with the following in-
hibitors for 1 h: AktiIV (10 μM), AktiV (5 μM), AktiVIII (5 μM), or 25HC (2.5 μM). The
cells were then treated with or without IGF-1 (20 nM) for a further 1 h (for protein
harvest), or 2 h (for mRNA harvest). (A) Whole cell lysates were subjected to SDS-
PAGE and then transferred to nitrocellulose membranes. Membranes were probed for
SREBP-2, pAkt, Akt, and α-tubulin. P and M denote the precursor and mature forms
of SREBP-2, respectively. Western blots are representative of three separate experi-
ments, and the relative intensity (M) value represents the densitometric quantiﬁcation
of the mature form of SREBP-2, where the +IGF-1 condition has been set to 1. (B) Total
RNA was harvested and reverse transcribed to cDNA, and gene expression levels of the
LDLR and HMGCR were quantiﬁed using qRT-PCR, and normalised to the housekeeping
gene, PBGD. Data are presented relative to the +IGF-1 condition which has been set to
1. Data were from 3 to 5 separate experiments, each performed in triplicate, and are
presented as mean+SEM.
Fig. 4. Akt siRNA decreased IGF-1-induced SREBP-2 activation, and rapalog-activated
Akt increased SREBP-2 activation. (A) CHO-7 cells were seeded, transfected with con-
trol siRNA (200 nM) or Akt siRNA (200 nM), fresh media was added every 24 h for
48 h, and then cells were serum-starved overnight. The cells were treated with or with-
out IGF-1 (20 nM) for a further 1 h. (B) Stable cell-lines (expressing Akt or empty vec-
tor; EV) were seeded, serum-starved overnight, and then treated with or without
rapalog (0.5 μM) for 1 h. Whole cell lysates from (A) and (B) were subjected to SDS-
PAGE and then transferred to nitrocellulose membranes. Membranes were probed for
SREBP-2, pAkt, Akt, α-tubulin. For (B), the bands corresponding to the 56 kDa endoge-
nous pAkt/Akt and the ~75 kDa FRB-Akt are as indicated. P and M denote the precursor
and mature forms of SREBP 2, respectively. Western blots are representative of at least
two separate experiments, and the relative intensity (M) value represents the densito-
metric quantiﬁcation of the mature form of SREBP-2, where the maximal condition
(lane 2 for each panel) has been set to 1.
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brought to the membrane in close proximity to its activating proteins
(PDK1 and mTOR complex 2), thereby activating Akt in a targeted
manner.
Indeed, rapalog activated FRB-Akt-Myc in the stable cell-line
(Fig. 4B). Importantly, SREBP-2 was also activated upon rapalog addi-
tion in the FRB-Akt-Myc stable cell-line and not the empty vector
control cell-line. These results provide another line of evidence that
Akt activates SREBP-2 acutely.
4. Discussion
Recent evidence suggests that PI3K/Akt activates the SREBPs, mas-
ter transcriptional regulators of lipid metabolism [7]. Most studies
have focused on SREBP-1c, involved in fatty acid metabolism. The
link between PI3K/Akt and the predominant isoform involved in cho-
lesterol metabolism, SREBP-2, is less well-deﬁned. Therefore, this in-
vestigation aimed to expand our knowledge in this area, and here
we have strengthened and extended previous studies (including our
own [14]) in several ways. Firstly, instead of relying on proxy mea-
sures, we have determined mature SREBP-2 directly by Western blot-
ting throughout. Secondly, we have used a key growth factor, IGF-1,which is well-documented to signal through Akt [17]. Thirdly, we
have minimised the chances of pleiotropic effects, by studying acute
time-points. Finally, we have used a multitude of pharmacological
and molecular tools to induce and reduce Akt activation.
Our major ﬁnding is that activation of the Akt pathway positively
modulates SREBP-2 activation acutely. Pharmacologically inhibiting
PI3K (LY294002 and wortmannin) or Akt (Akt inhibitors IV, V and
VIII) reduced IGF-1-induced SREBP-2 activation, indicating the in-
volvement of the PI3K/Akt pathway (Figs. 1, 2, 3, and Supplementary
Fig. 1). By using three Akt inhibitors that have distinct structures and
differing modes of action, we have ensured that the effects we have
observed are in fact due to Akt inhibition, and not artefactual. A genet-
ic approach of silencing Akt with siRNA conﬁrmed the correlation be-
tween Akt and SREBP-2 activation (Fig. 4A). Furthermore, the use of
the rapalog heterodimerisation system further strengthened the ﬁnd-
ing that activating Akt causes SREBP-2 activation (Fig. 4B). As well as
inhibiting the formation of mature SREBP-2, downstream gene targets
were also regulated by Akt (Fig. 3B). The effects of Akt inhibitor
on SREBP-2 mature protein levels mirrored the downregulation of
463W. Luu et al. / Biochimica et Biophysica Acta 1823 (2012) 458–464SREBP-2 target genes (LDLR and HMGCR), consistent with SREBP-2 ac-
tivity being regulated by Akt.
By using multiple, independent lines of evidence we have compre-
hensively indicated that the Akt pathway upregulates the SREBP-2
pathway. The interplay between these two pathways is reasonable,
given that Akt is involved in cell growth and proliferation, and
SREBP-2 is needed for cholesterol production, which in turn is re-
quired for new membranes for cell growth. Akt is a positive effector
which can amplify this process whereas sterols are the over-riding
negative regulator. Accordingly, 25HC ablated SREBP-2 activation
when Akt was stimulated by IGF-1 (Figs. 1B, 2A, 3, and Supplementary
Fig. 2).
The molecular mechanism by which Akt activates SREBP-2 is con-
troversial, as discussed elsewhere [7]. Proposed mechanisms include
increased trafﬁcking and processing [14] and reduced degradation
of SREBP [40]. We have evidence for the involvement of ER-to-Golgi
transport of SREBP-2, in that IGF-1-dependent trafﬁc of the SREBP-2
escort protein Scap was impeded by Akt inhibition (Fig. 2C). While
sterol addition effectively abolished mature SREBP-2 with an accom-
panying increase in SREBP-2 precursor, Akt inhibition generally re-
duced both precursor and mature forms. This suggests that Akt's
effect, unlike that of sterols, is not solely due to reduced SREBP-2 pro-
cessing. For example, there was some suggestion that proteasomal in-
hibition stabilised the mature form of SREBP-2 in response to Akt
inhibition, consistent with reduced degradation (Fig. 2B), as observed
for SREBP-1a and -1c [40].
The precise target(s) of Akt that affects SREBP-2 remains elusive.
We have recently shown that the coatomer protein II cargo selection
protein Sec24, involved in the transport of the SREBP-2/Scap complex
from the ER to the Golgi [12] is phosphorylated by Akt [41]. However,
we have been unable to demonstrate that Sec24 phosphorylation by
Akt contributes to the increased SREBP-2 activation observed. A sig-
nalling hub downstream of Akt, mTOR Complex 1, is involved in
SREBP-1c activation [42,43], but does not appear to mediate SREBP-
2 activation, at least in this system, since the inhibitor of this complex,
rapamycin, did not affect IGF-1 stimulated SREBP-2 processing in CHO
cells [44].
Taken together, our data provide persuasive evidence that Akt in-
ﬂuences SREBP-2 activation. Considering that Akt and lipids play cru-
cial roles in a number of diseases, including diabetes, viral infections
and cancer (reviewed in [7]), an Akt–SREBP-2 link may yield fresh
perspectives into human health and disease. Further research is re-
quired to identify the Akt effector(s) and how they interact with
SREBP-2 to inﬂuence its activity.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.09.017.Acknowledgements
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